CD8A and cancer: Furthermore, in TILs, CD133+CD44+ cancer stem cells (CSCs) have the ability to impair the function of cytotoxic CD8+ T cells (CTLs) in TME by altering the expression of their programmed-death ligand 1 (PD-L1) receptor.